MedCity News
J.P. Morgan’s life sciences outlook for 2021
Peter Meath, J.P. Morgan Commercial Banking’s Co-Head of Healthcare and Life Sciences, applies lessons from 2020’s remarkable second half and shares insights on what to expect in 2021.
Shares0
Source: J.P. Morgan
To call 2020 a “unique year” for life sciences companies would be an understatement. The COVID-19 pandemic transformed the industry, creating immense opportunities for institutions and investors to drive healthcare through innovation.
Peter Meath, Co-Head of Healthcare and Life Sciences for Middle Market Commercial Banking at J.P. Morgan, notes that investment in life sciences reached record-high levels across almost every category and subsector despite unprecedented business challenges. Here are a few of the highlights:
MedCity News
United Therapeutics notches another FDA approval for lung drug
The FDA decision for Tyvaso as a treatment for pulmonary arterial hypertension in patients who have interstitial lung disease is the second approval for the United Therapeutics drug. The additional indication gives the company another way to grow revenue for the drug, which faces generic competition.
Shares0
United Therapeutics has received FDA approval for its drug, treprostinil, as a treatment for high blood pressure affecting the lungs in patients who have a group of rare respiratory disorders called interstitial lung diseases.
The regulatory nod is the second for the inhaled version of treprostinil, which was initially approved in 2009 as a treatment for pulmonary arterial hypertension high blood pressure in the arteries that carry blood from the heart to the lungs. Silver Spring, Maryland-based United Therapeutics also sells the drug in injectable and oral formulations. Together, the three ver
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
MedCity News
Grand Rounds strikes merger with Doctor on Demand
In another big tie-up between a telehealth and digital health company, Grand Rounds and Doctor on Demand reached a merger agreement. Grand Rounds CEO Owen Tripp will serve as CEO of the combined business.
Shares1
When Teladoc closed its $18.5B acquisition of Livongo, it set the stage for more mergers to come. Now, two more established digital health companies are pairing up.
On Tuesday, Grand Rounds announced plans to merge with Doctor on Demand, creating a company that would build on Grand Rounds’ care navigation services with the latter’s telehealth platform.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.